816 related articles for article (PubMed ID: 16361330)
1. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis.
Rouse MS; Piper KE; Jacobson M; Jacofsky DJ; Steckelberg JM; Patel R
J Antimicrob Chemother; 2006 Feb; 57(2):301-5. PubMed ID: 16361330
[TBL] [Abstract][Full Text] [Related]
2. Regional antibiotic delivery for the treatment of experimental prosthetic graft infections.
Keeling WB; Myers AR; Stone PA; Heller L; Widen R; Back MR; Johnson BL; Bandyk DF; Shames ML
J Surg Res; 2009 Dec; 157(2):223-6. PubMed ID: 19560786
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus.
Vaudaux P; Francois P; Bisognano C; Li D; Lew DP; Schrenzel J
J Antimicrob Chemother; 2003 Jul; 52(1):89-95. PubMed ID: 12775678
[TBL] [Abstract][Full Text] [Related]
4. Characterization of biodegradable chitosan microspheres containing vancomycin and treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with prepared microspheres.
Cevher E; Orhan Z; Mülazimoğlu L; Sensoy D; Alper M; Yildiz A; Ozsoy Y
Int J Pharm; 2006 Jul; 317(2):127-35. PubMed ID: 16624509
[TBL] [Abstract][Full Text] [Related]
5. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin.
Vikram HR; Havill NL; Koeth LM; Boyce JM
J Clin Microbiol; 2005 Oct; 43(10):5384-7. PubMed ID: 16208025
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis.
Lefebvre M; Jacqueline C; Amador G; Le Mabecque V; Miegeville A; Potel G; Caillon J; Asseray N
Int J Antimicrob Agents; 2010 Dec; 36(6):542-4. PubMed ID: 20851576
[TBL] [Abstract][Full Text] [Related]
7. Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis.
Gerber P; Stucki A; Acosta F; Cottagnoud M; Cottagnoud P
J Antimicrob Chemother; 2006 Apr; 57(4):720-3. PubMed ID: 16459345
[TBL] [Abstract][Full Text] [Related]
8. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
[TBL] [Abstract][Full Text] [Related]
9. Daptomycin for methicillin-resistant Staphylococcus aureus infections of the spine.
Burdette SD
Spine J; 2009 Jun; 9(6):e5-8. PubMed ID: 19112049
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.
Ahmad NM; Rojtman AD
Ann Pharmacother; 2010 May; 44(5):918-21. PubMed ID: 20354160
[TBL] [Abstract][Full Text] [Related]
11. The use of daptomycin for Staphylococcus aureus infections in critical care medicine.
Alder J
Crit Care Clin; 2008 Apr; 24(2):349-63, ix-x. PubMed ID: 18361950
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry.
Martone WJ; Lamp KC
Curr Med Res Opin; 2006 Dec; 22(12):2337-43. PubMed ID: 17257448
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.
Dandekar PK; Tessier PR; Williams P; Nightingale CH; Nicolau DP
J Antimicrob Chemother; 2003 Sep; 52(3):405-11. PubMed ID: 12917254
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of hydroxyapatite-vancomycin bone cement in the treatment of Staphylococcus aureus induced chronic osteomyelitis.
Joosten U; Joist A; Gosheger G; Liljenqvist U; Brandt B; von Eiff C
Biomaterials; 2005 Sep; 26(25):5251-8. PubMed ID: 15792552
[TBL] [Abstract][Full Text] [Related]
15. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
Bennett JW; Murray CK; Holmes RL; Patterson JE; Jorgensen JH
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
[TBL] [Abstract][Full Text] [Related]
16. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin.
Skiest DJ
J Clin Microbiol; 2006 Feb; 44(2):655-6. PubMed ID: 16455939
[TBL] [Abstract][Full Text] [Related]
17. Daptomycin: rationale and role in the management of skin and soft tissue infections.
Seaton RA
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii15-23. PubMed ID: 18829721
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci.
Vouillamoz J; Moreillon P; Giddey M; Entenza JM
J Antimicrob Chemother; 2006 Dec; 58(6):1208-14. PubMed ID: 17030515
[TBL] [Abstract][Full Text] [Related]
19. Long-term use of daptomycin for MRSA osteomyelitis and joint infection.
Burns CA
Scand J Infect Dis; 2008; 40(2):183-6. PubMed ID: 17852899
[TBL] [Abstract][Full Text] [Related]
20. Intermediate vancomycin susceptibility in a community-associated MRSA clone.
Graber CJ; Wong MK; Carleton HA; Perdreau-Remington F; Haller BL; Chambers HF
Emerg Infect Dis; 2007 Mar; 13(3):491-3. PubMed ID: 17552110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
